Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.36 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 5/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7045767 | 0.91 | MAPT (0.37) | CRHR1LMNAMEN1HTTKMT2A | |
| SCHEMBL7043666 | 0.84 | MAPT (0.47) | LMNAHTTMAPTMAPK1SMN1; SMN2 | |
| SCHEMBL7046809 | 0.82 | MAPT (0.39) | LMNAMEN1HTTKMT2AMAPT | |
| SCHEMBL7045359 | 0.80 | PPIA (0.40) | NPC1RAB9ALMNAMEN1KMT2A | |
| SCHEMBL7046838 | 0.76 | MAPT (0.49) | NPC1RAB9AMEN1HTTKMT2A | |
| SCHEMBL7042024 | 0.76 | MAPT (0.46) | LMNAHTTMAPTTP53 | |
| SCHEMBL6696475 | 0.74 | CRHR1 (0.39) | CRHR1NPC1TSHRRAB9AAGTR1 | |
| SCHEMBL27576511 | 0.74 | CRHR1 (0.39) | CRHR1AGTR1AGTR2MAPK8LMNA | |
| SCHEMBL7043673 | 0.72 | LMNA (0.50) | NPC1RAB9ALMNAHTTKMT2A | |
| SCHEMBL7043420 | 0.69 | NPC1 (0.43) | NPC1RAB9AMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002064096-A9 | METHODS OF USING PYRIMIDINE-BASED ANTIVIRAL AGENTS | TULARIK INC (US) | 2003-10-16 | — | — | WO | disclosed |
| US-20030130264-A1 | Methods of using pyrimidine-based antiviral agents | TULARIK INC. (US) | 2003-07-10 | — | — | US | disclosed |
| WO-2002064096-A2 | METHODS OF USING PYRIMIDINE-BASED ANTIVIRAL AGENTS | TULARIK INC. (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130264-A1 | Methods of using pyrimidine-based antiviral agents | TYMP, TYMS, NUDT1 | CRHR1 4562/4885NPC1 2289/4885TSHR 4783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.